About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608
Dynavax Technologies Corporation News and around…
Latest news about Dynavax Technologies Corporation (DVAX) common stock and company :
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
One of its vaccine partners had some encouraging regulatory news to report.
The company earns an Emergency Use Authorization from a well-off Middle Eastern country.
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022.
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend ...
Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies ...
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:
Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 29.7% to $0.21 during Thursday's after-market session. Today's ...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Rocket Companies Inc Class A (RKT), where a total volume of 35,441 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.6% of RKT's average daily trading volume over the past month, of 4.7 million shares..
Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.
DVAX earnings call for the period ending March 31, 2022.
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided business updates for the three months ending March 31, 2022.
Clover Biopharmaceuticals Ltdannouncednew promising data from a preclinical studyon its bivalent vaccine candidate, ...
-- Bivalent candidate (Prototype + Omicron) demonstrates broad neutralization against Omicron and all VoCs in both primary vaccination and booster settings in preclinical study -- -- Potential to pursue licensure pathway based on immuno-bridging to prototype vaccine candidate SCB-2019 (CpG 1018/Alum) which utilizes the validated Trimer-Tag™ technology platform -- SHANGHAI, China, May 05, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biote
While Dynavax Technologies Corporation ( NASDAQ:DVAX ) shareholders are probably generally happy, the stock hasn't had...
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial markets close.
Investors in Dynavax Technologies Corp (DVAX) saw new options begin trading this week, for the June 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DVAX options chain for the new June 17th contracts and identified one put and one call contract of particular interest.
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 28,250 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.
Dynavax Technologies (NASDAQ:DVAX) has had a rough three months with its share price down 20%. But if you pay close...
Several coronavirus vaccines using the company's adjuvant are advancing up the regulatory ladder.
SHANGHAI, China, March 17, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Clover Biopharmaceuticals (Clover; HKEX: 2197), please note that in the third bullet point describing preliminary data from ongoing clinical trials, the results were based in individuals "previously receiving two doses of SCB-2019 (CpG 1018/Alum) primary vaccination," not "previously infected with SARS CoV 2" as was previously stated. The corrected release follows: Clover’s COVID-19 V
These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q2 2022.
Clover Biopharmaceuticals Ltd'sfollow-up analysis for efficacyin the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets ...
--100% efficacy maintained against severe COVID-19 and 95% efficacy against hospitalization at five months after second dose of SCB-2019 (CpG 1018/Alum)-- --Significant neutralizing antibodies against Omicron induced by SCB-2019 (CpG 1018/Alum) third dose in both homologous and heterologous booster settings-- SHANGHAI, China, March 17, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 2197), a global clinical-stage biotechnology company developing novel vaccines and biologi
The broader stock market bounce and news from China are fueling gains for all four vaccine stocks.
Dynavax Technologies Corporation (DVAX) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
